SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has raised fears that it could eventually compete with T-Mobile and other wireless carriers, contributing to a sharp selloff. Traders are divided over whether the move signals a serious long-term threat or an overreaction, given the infrastructure and time needed to build a competitive network.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

The FDAs acceptance of Intellias lonvo-z application with Priority Review is driving discussion, moving its potential one-time HAE gene-editing treatment closer to a regulatory decision. Bulls see major commercial potential, while skeptics point to financing and launch risks and question why the share price has responded weakly; traders also cite continued ARK buying.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoins rally and elevated trading activity are drawing attention, with traders pointing to Eightcos disclosed 8.4% stake and the tokens potential role in verifying people amid growing AI use. Sentiment is largely bullish, though some traders question whether the move is sustainable and cite volatility and speculative hype.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs rally is being driven by anticipation of founder Patrick Soon-Shiongs upcoming oncology symposium fireside chat, where traders expect updates on clinical trials and the companys immunotherapy pipeline. Speculation about a partnership and a possible short squeeze is adding to the bullish chatter, but those remain unconfirmed.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas non-binding LOI to acquire its first U.S. data center and expand toward a 100+ MW AI infrastructure portfolio is driving discussion. Some traders view U.S. expansion as a positive step, while many are skeptical about the deals financing and execution and want updates on existing deployments such as Yotta.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

A sharp pullback after a strong earnings-driven rally is fueling debate, with bulls citing Digital Turbines growth, cash flow and app-distribution opportunities while bears point to continued selling, debt or dilution concerns, and a lack of fresh catalysts. Traders are also watching the next earnings report for evidence that recent business momentum can continue.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

Exchange delisting concerns and JASMYs weak, volatile price action are driving debate, with some traders warning of further downside while others say specific exchange changes are being misrepresented or are limited in scope. Bulls also point to rising JasmyChain activity and ecosystem development as signs of emerging utility, though skeptics question whether that activity will translate into meaningful adoption or token demand.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Lennar is drawing attention after a Hunterbrook short report questioned its transactions with spinoff Millrose, alleging Millrose bought hundreds of Lennar homes and raising concerns about related-party sales and reported deliveries. Traders are split between viewing Berkshire Hathaways substantial stake as a vote of confidence and focusing on the allegations, weak housing demand, and elevated mortgage rates.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is drawing attention around its Coinbase listing and Midnights network rollout, including Google Clouds validator involvement. Traders welcome the added access and infrastructure milestones, though reactions are mixed as some see room for a recovery while others point to weak follow-through and nearby resistance.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances stronger commercial outlook, tied to Amtagvi demand and a raised revenue forecast, is fueling renewed interest alongside discussion of falling short interest. Traders are also positioning around upcoming ESMO cancer data, earnings and an NSCLC update, while some caution that the sharp run-up leaves the stock vulnerable to profit-taking and biotech-sector volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich AtaxiaPR NewswireNEW YORK, Sept. 23, 2026 NEW YORK, Sept. 23, 2026...

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.read more...

Lexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia

(RTTNews) - Lexeo Therapeutics, Inc. (LXEO), a clinical stage company, announced Tuesday a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire private clinical stage company Mantle Therapeut...

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple...

Why Is Lexeo Therapeutics Stock Gaining Monday?

Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment set to begin in June 2026.read more...

Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-lexeo-therapeutics-inc-stock...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one...

Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen cut Lexeo Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2%  - Should You Buy?

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 3.2% - Here's What Happened...

Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 55,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.32	--	--	N/A
Q2 '26	-$0.29	-$0.30	-5.20%	MISSED
Q1 '26	-$0.31	-$0.25	19.13%	BEAT
Q4 '25	-$0.31	-$0.27	14.23%	BEAT
Q3 '25	-$0.52	-$0.33	36.54%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXEO Earnings

Upcoming Earnings: Q3 '26

Historical Earnings